Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
More FUD for your reading enjoyment.
I'm looking forward to the February update ,so that I can hear from the company. That's where I get my information from.
Decent volume. Some adding before next update ?
Hey , that write up said 6 cents not .0535.
What bs. Can’t believe a word of it .
Lololol
March 1st one week away . Looking forward to the February monthly update .
IDE submission followed by a probable approval will take care of the share price and all of the FUD posted by the ex employee.
The IDE submission and approval will force the disgruntled ex employee to find another job . It’s coming
About a week until March, and looking forward to the February update. Keep in mind we have the guidance of the FDA during the IDE process which greatly increases the likelihood of an IDE APPROVAL. Human trials at the Mayo Clinic will follow shortly thereafter. Buckle up.
The submission process you won't be a part of. Same with the approval. Keep posting FUD/BS
So glad Dr Korenko cleaned house before embarking upon the IDe process. Imagine having that disgruntled ex employee complaining 24/7 during the submission process.
Some people are in their own little world.
Yawn
The upcoming IDE submission and probable approval will clean up this board.
“We”. Lol
He’s here promoting his own agenda . IDE submission and subsequent approval will force him to find new employment and bash a new stock/company .
100 % agree
IDE submission and probable IDE APPROVAL will clean this board up and some will be looking for new employment.
This will be happening sooner than some think .
I care what happened years ago . Dr Korenko cleaned house before embarking upon the IDE process . Imagine the disgruntled employee complaining every step of the way in the process . Instead we get to hear the daily complaints.
Those posts are only to drown out SC8. Tske your pick .
The guy complaining the most about this company and its CEO, still owns shares in this company. Interesting.
Michael K. Korenko, Sc.D.
President • CEO Vivos, Inc.
Mike Korenko has a Doctor of Science from MIT, was a NATO Postdoctoral Fellow at Oxford University, and was selected as a White House Fellow for the Department of Defence.
He currently is the author of 28 patents and has received many awards, including the National Energy Resources Organization Research and Development Award, the U.S. Steelworkers Award for Excellence in Promoting Safety, and the Westinghouse Total Quality Award for Performance Manager of the Year.
Dr. Korenko served as Vice-President of Westinghouse Hanford, Executive Vice President of Closure at Rocky Flats and Chief Operating Officer for Curtiss-Wright Electro-Mechanical Division producer of the nuclear components for all the United States submarines and aircraft carriers and for commercial nuclear power reactors.
He is currently CEO and President of Vivos Inc. developing yttrium-90 brachytherapy for animals and humans.
Vivos Inc. has researched and developed patents related to the RadioGel™ device technology for use in high-dose radiation therapy. These patents have established our independence and no longer relying on external sources.
Vivos may have made, use and market RadioGel™ as a medical device. Yttrium-90 is a well-established medical isotope with many applications in cancer treatment. The combination of insoluble yttrium-90 particles and the polymer gel carrier offers physicians an opportunity to deliver a safe, effective treatment option at a reasonable cost.
Yes he does .
If you’re new here , you’ll figure out in time SC8 posts nonstop FUD .
EVERYONE ignores him . Responding to his posts just generates more nonstop FUD .
The FDA’s Breakthrough Devices program will enhance the
schedule priority for our upcoming IDE submission seeking authorization to begin human clinical trials.
Michael K. Korenko, Sc.D.
President • CEO Vivos, Inc.
Mike Korenko has a Doctor of Science from MIT, was a NATO Postdoctoral Fellow at Oxford University, and was selected as a White House Fellow for the Department of Defence.
He currently is the author of 28 patents and has received many awards, including the National Energy Resources Organization Research and Development Award, the U.S. Steelworkers Award for Excellence in Promoting Safety, and the Westinghouse Total Quality Award for Performance Manager of the Year.
Dr. Korenko served as Vice-President of Westinghouse Hanford, Executive Vice President of Closure at Rocky Flats and Chief Operating Officer for Curtiss-Wright Electro-Mechanical Division producer of the nuclear components for all the United States submarines and aircraft carriers and for commercial nuclear power reactors.
He is currently CEO and President of Vivos Inc. developing yttrium-90 brachytherapy for animals and humans.
Sure thing MC73,, you and your buddies keep spreading your own "reality"
The FUD is getting pretty weak these days .
Oh well
Especially coming from a very conservative CEO in Dr Korenko
Getting things ready for human trials with the MAYO clinic .
RadioGel™ – compared to current brachytherapy treatment technology
Next-Generation Breakthrough cancer treatment
Based upon its studies and analyses, or general application of experience with current brachytherapy devices and Yttrium-90, Vivos believes that its brachytherapy products are likely to offer the following benefits, among others, for patients and medical professionals:
• Maximizing Therapeutic Index: The short-range beta particles emitted by Y-90 deliver radiation energy within a tight range. This enables radiation to be selectively delivered to target tissues while minimizing radiation dose to nearby normal tissues. High therapeutic indices imply that more radiation energy may be imparted to target tissues, with less radiation reaching adjacent normal tissues.
• Half Life: Y-90 has a half-life of just 2.7 days. Many traditional brachytherapy products use isotopes with longer half-lives such as 9.7 days for cesium-131, and sixty days for iodine-125.
Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area. The product delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows safe delivery of higher doses needed for treating both non-resectable and radiation-resistant cancers.
According to Global Industry Analysts, by 2027 the Global brachytherapy market will reach $550 million (USD). It is estimated that the U.S. market represents approximately half of the global market. Vivos believes there are significant opportunities in prostate, breast, liver, pancreatic, head and neck cancers. The 2019 U.S. estimated new cases according to the American Cancer Society are 240,000 prostate cancer, 235,000 breast cancer and 31,000 liver cancer.
Precision Radionuclide Therapy (PRnT)™
The future of brachytherapy cancer treatment – the insertion of our radionuclide device directly into the tumor tissue.
Michael K. Korenko, Sc.D.
President • CEO Vivos, Inc.
Mike Korenko has a Doctor of Science from MIT, was a NATO Postdoctoral Fellow at Oxford University, and was selected as a White House Fellow for the Department of Defence.
He currently is the author of 28 patents and has received many awards, including the National Energy Resources Organization Research and Development Award, the U.S. Steelworkers Award for Excellence in Promoting Safety, and the Westinghouse Total Quality Award for Performance Manager of the Year.
Dr. Korenko served as Vice-President of Westinghouse Hanford, Executive Vice President of Closure at Rocky Flats and Chief Operating Officer for Curtiss-Wright Electro-Mechanical Division producer of the nuclear components for all the United States submarines and aircraft carriers and for commercial nuclear power reactors.
He is currently CEO and President of Vivos Inc. developing yttrium-90 brachytherapy for animals and humans.
Michael K. Korenko, Sc.D.
President • CEO Vivos, Inc.
Mike Korenko has a Doctor of Science from MIT, was a NATO Postdoctoral Fellow at Oxford University, and was selected as a White House Fellow for the Department of Defence.
He currently is the author of 28 patents and has received many awards, including the National Energy Resources Organization Research and Development Award, the U.S. Steelworkers Award for Excellence in Promoting Safety, and the Westinghouse Total Quality Award for Performance Manager of the Year.
Dr. Korenko served as Vice-President of Westinghouse Hanford, Executive Vice President of Closure at Rocky Flats and Chief Operating Officer for Curtiss-Wright Electro-Mechanical Division producer of the nuclear components for all the United States submarines and aircraft carriers and for commercial nuclear power reactors.
He is currently CEO and President of Vivos Inc. developing yttrium-90 brachytherapy for animals and humans.
2 new hires , BDD in hand , IDE submission next followed by probable APPROVAL, followed by human trials at the Mayo Clinic . Going to be a fantastic year !
2 new hires , BDD in hand , IDE submission next followed by probable APPROVAL, followed by human trials at the Mayo Clinic . Going to be a fantastic year !
Shows how confident Dr Korenko is about receiving the IDE.
It’s understandable. Those that actually own shares want the same outcome . I appreciate the transparency we have from this last monthly update .
We’ll get there .
I understand that ,, point I’m making is we could have submitted the IDE a while ago only to have it denied . Is it taking longer than I’d like ? Yes . For those who own shares and aren’t happy with the time frame , they’re free to sell their shares .
No need to name call .
Agree ,, we now have a more definitive timeline.
I keep saying what’s important is not the IDE submission but an IDE APPROVAL.
Dr Korenko is giving us the best chance of that IDE APPROVAL
BDD in hand,,, 2 new hires,,, Final training for Mayo this month,,,, looks like things are happening and fast. IDE submission just around the corner imo.